CN105229151A - 包含包封的antagomir的组合物 - Google Patents

包含包封的antagomir的组合物 Download PDF

Info

Publication number
CN105229151A
CN105229151A CN201480017728.3A CN201480017728A CN105229151A CN 105229151 A CN105229151 A CN 105229151A CN 201480017728 A CN201480017728 A CN 201480017728A CN 105229151 A CN105229151 A CN 105229151A
Authority
CN
China
Prior art keywords
mir
sequence
seqidno
nucleotide identity
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480017728.3A
Other languages
English (en)
Chinese (zh)
Inventor
M-A·阿莘
E·费雷特
A·佩雷兹
N·B·戈塔尔达
A·罗德里奎兹西诺瓦斯
I·B·瓦尔特
A·D·加西亚-多拉多加西亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundació Institut de Recerca Hospital Universitari Vall d'Hebron
Pierre Fabre Medicament SA
Original Assignee
Fundació Institut de Recerca Hospital Universitari Vall d'Hebron
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Institut de Recerca Hospital Universitari Vall d'Hebron, Pierre Fabre Medicament SA filed Critical Fundació Institut de Recerca Hospital Universitari Vall d'Hebron
Publication of CN105229151A publication Critical patent/CN105229151A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480017728.3A 2013-01-24 2014-01-23 包含包封的antagomir的组合物 Pending CN105229151A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13305082.3A EP2759595B1 (en) 2013-01-24 2013-01-24 Composition comprising an encapsulated antagomir
EP13305082.3 2013-01-24
PCT/IB2014/058500 WO2014115103A1 (en) 2013-01-24 2014-01-23 Composition comprising an encapsulated antagomir

Publications (1)

Publication Number Publication Date
CN105229151A true CN105229151A (zh) 2016-01-06

Family

ID=47683670

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480017728.3A Pending CN105229151A (zh) 2013-01-24 2014-01-23 包含包封的antagomir的组合物

Country Status (16)

Country Link
US (1) US20150352055A1 (cg-RX-API-DMAC7.html)
EP (2) EP2759595B1 (cg-RX-API-DMAC7.html)
JP (1) JP2016506923A (cg-RX-API-DMAC7.html)
KR (1) KR20160018451A (cg-RX-API-DMAC7.html)
CN (1) CN105229151A (cg-RX-API-DMAC7.html)
AU (1) AU2014208419A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015017650A2 (cg-RX-API-DMAC7.html)
CA (1) CA2898958A1 (cg-RX-API-DMAC7.html)
ES (2) ES2606636T3 (cg-RX-API-DMAC7.html)
HK (1) HK1219753A1 (cg-RX-API-DMAC7.html)
HU (1) HUE032125T2 (cg-RX-API-DMAC7.html)
MX (1) MX2015009323A (cg-RX-API-DMAC7.html)
PL (1) PL2759595T3 (cg-RX-API-DMAC7.html)
RU (1) RU2668794C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014115103A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201505602B (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110484537A (zh) * 2019-09-02 2019-11-22 中国水产科学研究院淡水渔业研究中心 一种miR-92促进剂及其注射剂的制备方法和应用
CN110917359A (zh) * 2019-11-21 2020-03-27 武汉理工大学 离子键自组装制备PEG-P(Asp-AP)-ANTAGOMIR-RNA微球
CN111729088A (zh) * 2020-08-21 2020-10-02 江苏申基生物科技有限公司 一种微小核糖核酸miR-34a偶联探针及其制备方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2864482A4 (en) 2012-06-21 2016-02-10 Miragen Therapeutics Inc OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN
HK1249108A1 (zh) * 2015-01-20 2018-10-26 米拉根医疗股份有限公司 Mir-92抑制剂及其用途
EP3601565A4 (en) * 2017-03-25 2021-01-06 Miragen Therapeutics, Inc. MIR-92 INHIBITORS IN THE TREATMENT OF HEART FAILURE
EP3939575B1 (en) * 2019-03-14 2026-07-01 M. Technique Co., Ltd. PLGA MICROPARTICLES, DELAYED-RELEASE FORMULATION OF THESE AND THEIR MANUFACTURE PROCESS
CN110804659B (zh) * 2019-10-23 2023-02-03 华南农业大学 一种血清外泌体ssc-miR-92b-3p作为母猪早期妊娠诊断分子标志物的应用
WO2021251526A1 (ko) * 2020-06-11 2021-12-16 주식회사 프로스테믹스 신규한 mirna 유사체 및 이의 용도
WO2025050037A1 (en) * 2023-08-31 2025-03-06 The Regents Of The University Of Colorado, A Body Corporate Microrna-15b antagomir and cerium oxide nanoparticles, and uses of same for treatment of intrauterine growth restriction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7641643B2 (en) * 2003-04-15 2010-01-05 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
WO2005013901A2 (en) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
DK2205737T3 (da) * 2007-10-04 2013-05-21 Santaris Pharma As Mikromirer
DE102007052114B4 (de) * 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
GB0814302D0 (en) * 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
KR20120047214A (ko) * 2009-05-20 2012-05-11 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 심근경색 후 리모델링 및 심부전에 관련된 마이크로―rna의 확인

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANGELO ET AL: "Improved delivery of angiogenesis inhibitors from PLGA:poloxamer blend micro- and nanoparticles", 《J MICROENCAPSUL》 *
BONAUER ET AL: "MicroRNA-92a Controls Angiogenesis and Functional Recovery of Ischemic Tissues in Mice", 《SCIENCE》 *
DEEPAK等: "《纳米粒药物输送系统》", 30 September 2010, 北京大学医学出版社 *
FUJITA,ET AL: "Inhibition of MicroRNA-92a Enhances Angiogenesis and Cardiomyocyte Regeneration Through Integrin α5-Dependent Accumulation of Stem Cells Into the Infarcted Myocardium", 《CIRCULATION》 *
JAYANTH ET AL: "B iodegradable nanoparticles for drug and gene delivery to cells and tissue", 《ELSEVIER SCIENCE 》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110484537A (zh) * 2019-09-02 2019-11-22 中国水产科学研究院淡水渔业研究中心 一种miR-92促进剂及其注射剂的制备方法和应用
CN110917359A (zh) * 2019-11-21 2020-03-27 武汉理工大学 离子键自组装制备PEG-P(Asp-AP)-ANTAGOMIR-RNA微球
CN111729088A (zh) * 2020-08-21 2020-10-02 江苏申基生物科技有限公司 一种微小核糖核酸miR-34a偶联探针及其制备方法

Also Published As

Publication number Publication date
KR20160018451A (ko) 2016-02-17
US20150352055A1 (en) 2015-12-10
PL2759595T3 (pl) 2017-09-29
EP2759595A1 (en) 2014-07-30
CA2898958A1 (en) 2014-07-31
JP2016506923A (ja) 2016-03-07
ES2606636T3 (es) 2017-03-24
WO2014115103A1 (en) 2014-07-31
HUE032125T2 (en) 2017-08-28
AU2014208419A1 (en) 2015-08-13
EP2948551A1 (en) 2015-12-02
RU2015134770A (ru) 2017-03-03
BR112015017650A2 (pt) 2017-11-21
ZA201505602B (en) 2017-05-31
ES2688160T3 (es) 2018-10-31
EP2759595B1 (en) 2016-09-14
RU2668794C2 (ru) 2018-10-02
HK1219753A1 (zh) 2017-04-13
EP2948551B1 (en) 2018-05-02
MX2015009323A (es) 2016-04-04

Similar Documents

Publication Publication Date Title
EP2948551B1 (en) Composition comprising an encapsulated antagomir
CN102803284B (zh) 用于miRNA抑制剂和模拟物的化学修饰基序
EP2552454B1 (en) ANTAGONISTS OF miRNA-29 EXPRESSION AND THEIR USE IN THE PREVENTION AND TREATMENT OF AORTIC ANEURYSMS
KR102246814B1 (ko) 치료용 올리고뉴클레오타이드
JP2011256204A5 (cg-RX-API-DMAC7.html)
JP2013514372A (ja) 虚血および虚血−再灌流傷害におけるマイクロrna調節
JP2011256204A (ja) オリゴヌクレオチド含有マイクロスフェア、1型糖尿病を処置する医薬の製造のための、その使用
EP3765619B1 (en) Inhibitors of micro-rna 22
US9061068B2 (en) Polymeric nano-particles for siRNA delivery using charge interaction and covalent bonding
AU2023201262A1 (en) Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same
JP5888572B2 (ja) 神経保護の提供におけるマイクロrna195の使用法
KR20180005546A (ko) 약물이 탑재된 엑소좀 또는 나노베지클을 이용한 약학적 조성물
EP3329004B1 (en) Therapeutic oligonucleotides
Wang et al. MicroRNA delivery based on nanoparticles of cardiovascular diseases
US20240417734A1 (en) Methods for Treating Glioblastoma by Targeting Oncomirs
JPWO2015133637A1 (ja) マイクロrna封入ナノ粒子及びその医薬用途
Momin et al. The Challenges and Opportunities in the Development of MicroRNA Therapeutics: A Multidisciplinary Viewpoint. Cells 2021, 10, 3097
US20250161398A1 (en) Design and development of a novel messenger rna therapeutic to treat atherosclerosis
BR112018001782B1 (pt) Oligonucleotídeo para uso no tratamento e/ou prevenção de uma doença que compreende o alongamento alternativo dos telômeros, oligonucleotídeo para uso no tratamento e/ou prevenção de uma condição não cancerosa associada à disfunção do telômero e composição farmacêutica
CN120584186A (zh) 用于在静脉血栓栓塞的治疗中使用的药物组合物
BR122024021791A2 (pt) Oligonucleotídeo para uso no tratamento e/ou prevenção de uma doença que compreende o alongamento alternativo dos telômeros, oligonucleotídeo para uso no tratamento e/ou prevenção de uma condição não cancerosa associada à disfunção do telômero e composição farmacêutica
HK40045636B (en) Inhibitors of micro-rna 22
HK40045636A (en) Inhibitors of micro-rna 22
CN102140470A (zh) 人miR-1236反义核酸及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1219753

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160106

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1219753

Country of ref document: HK